Chlamydia Major Markets Asessment 2026: Highlights Expanding Screening and Vaccine Innovation

Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Chlamydia - Market Insights, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of chlamydia epidemiology, diagnosis, treatment practices, market dynamics and emerging clinical opportunities across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Covering historical and forecast data from 2022 to 2036, the report evaluates patient burden, treatment uptake, competitive positioning, market access and the future growth potential of the chlamydia therapeutics market.

Chlamydia Epidemiology and Market Trends

Chlamydia remains one of the most commonly reported bacterial sexually transmitted infections worldwide. The World Health Organization estimated 128.5 million new infections among adults globally in 2020. In Europe, 230,199 confirmed cases were reported across 27 EU/EEA countries in 2023, according to the European Centre for Disease Prevention and Control. Young adults continue to account for a substantial share of infections, with particularly high rates among women aged 15-24.

The United States continues to report a significant burden of urogenital chlamydia, while the United Kingdom identifies chlamydia as its most commonly diagnosed sexually transmitted infection. Within the EU4 and UK, Germany recorded the highest diagnosed incident population in 2025, with further growth projected through 2036. However, reported case totals remain influenced by screening coverage, healthcare access, reporting practices and the high proportion of asymptomatic infections.

Diagnosis, Screening and Current Treatment Landscape

Nucleic acid amplification tests remain the preferred diagnostic method, using urine or site-specific swab samples. Continued advances in point-of-care testing, including faster molecular platforms, are expected to improve diagnostic accessibility, reduce delays and support earlier treatment.

Screening programs are a major driver of the chlamydia market because they increase the identification of infections that might otherwise remain undiagnosed. Routine screening recommendations in markets such as the United States and the United Kingdom prioritize younger women, pregnant women and individuals with elevated infection risk. Government campaigns, public health programs, telemedicine and digital health services are also expanding access to testing, treatment and follow-up care.

Current management relies primarily on generic antibiotics. Doxycycline is widely recommended as a first-line regimen for uncomplicated infection, while azithromycin may be used in selected populations or when treatment adherence is a concern. Levofloxacin and amoxicillin may be considered in specific clinical circumstances. Although these therapies remain effective, the market continues to face limitations related to adherence, reinfection, partner management, treatment constraints and antimicrobial resistance concerns.

Unmet Needs and Chlamydia Market Opportunities

• Limited routine screening and continued underdiagnosis of asymptomatic infections
• Absence of a licensed preventive chlamydia vaccine
• High reinfection rates and limited durable protective immunity
• Dependence on generic broad- Spectrum antibiotics
• Need for targeted, long-acting and preventive interventions
• Uneven access to testing, treatment and follow-up services across geographies

The lack of pathogen-specific approved therapies across the 7MM creates a meaningful opportunity for pharmaceutical and diagnostic companies. Future market expansion is expected to be supported by improved screening, broader healthcare access, faster molecular diagnostics and the development of preventive vaccines. Nevertheless, antibiotics are projected to retain the largest treatment share during much of the forecast period because of their established efficacy, availability and inclusion in clinical guidelines.

Chlamydia Pipeline and Competitive Landscape

The chlamydia clinical pipeline remains limited and is concentrated on early-stage preventive approaches. Sanofi is among the companies advancing vaccine research through SP0269, an investigational mRNA vaccine candidate intended to prevent initial and recurrent genital tract infections caused by Chlamydia trachomatis. A Phase I/II randomized clinical trial is evaluating the candidate's safety and immune response in adults aged 18-29.

In March 2025, the chlamydia vaccine candidate received Fast Track designation from the US Food and Drug Administration, reflecting its potential to address a serious condition and an unmet public health need. If clinical development is successful, preventive vaccines could reshape the chlamydia market by reducing infection, reinfection and transmission rather than relying exclusively on post-diagnosis antibiotic treatment.

Diagnostic innovation is also advancing. In May 2025, Visby Medical submitted its Men's Sexual Health Test to the FDA for 510(k) clearance and a Clinical Laboratory Improvement Amendments waiver. The molecular test is designed to provide results for chlamydia and gonorrhea from male urine samples in under 30 minutes.

Chlamydia Market Forecast and Commercial Assessment

The report presents epidemiology-based market forecasts through 2036, including country-level patient populations, therapy uptake, revenue potential, market share, peak patient share and growth assumptions. It also examines pricing trends, analogue selection for emerging products, reimbursement conditions, cost-effectiveness and market access across the United States, Europe and Japan.

Commercial adoption of emerging therapies will depend on clinical efficacy, safety, durability, administration requirements, pricing, reimbursement and positioning within screening and prevention programs. SP0269 is expected to follow a measured uptake trajectory if approved, with adoption shaped by clinical evidence, public health recommendations and access to vaccination services.

Report Scope and Strategic Value

• Chlamydia epidemiology and patient population forecasts across the 7MM
• Historical and projected chlamydia market size from 2022 to 2036
• Current treatment practices and evolving clinical algorithms
• Pipeline analysis and profiles of emerging chlamydia therapies
• Drug uptake, peak patient share and commercial performance forecasts
• Competitive landscape, strategic partnerships and regulatory catalysts
• Pricing, reimbursement and market access analysis
• SWOT and conjoint analysis of emerging therapeutic approaches
• Key opinion leader insights and country-specific physician perspectives

Primary research includes insights from more than 15 key opinion leaders and subject matter experts, supported by secondary analysis and epidemiology-based forecasting. The report is designed to help pharmaceutical companies, investors, healthcare organizations and other stakeholders evaluate chlamydia market opportunities, prioritize pipeline assets, anticipate adoption barriers and develop evidence-based commercial strategies through 2036.

Key Topics Covered

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow

5. Epidemiology and Market Methodology of Chlamydia

6. Chlamydia Market Overview at a Glance
6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of Chlamydia By Therapies (%) in the 7MM in 2025
6.3. Market Share of Chlamydia By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Chlamydia
7.1. Introduction
7.2. Causes
7.3. Signs And Symptoms
7.4. Diagnosis
7.4.1. Differential Diagnosis
7.4.2. Diagnostic Algorithm
7.4.3. Diagnostic Guidelines
7.5. Treatment and Management
7.5.1. Centers for Disease Control and Prevention, Sexually Transmitted Infections Treatment Guidelines

8. Epidemiology and Patient Population of Chlamydia
8.1. Key Findings
8.2. Assumption and Rationale
8.3. Total Fina Elf Incident Cases of Chlamydia in the 7MM
8.4. The United States
8.4.1. Total Fina Elf Incident Cases of Chlamydia in the United States
8.4.2. Vaccine Eligible Pool of Chlamydia in the United States
8.4.3. Gender-specific Incident Cases of Chlamydia in the United States
8.4.4. Symptom-specific Incident Cases of Chlamydia in the United States
8.4.5. Age-specific Incident Cases of Chlamydia in the United States
8.4.6. Treated Cases of Chlamydia in the United States
8.5. EU4 and the UK
8.5.1. Total Fina Elf Incident Cases of Chlamydia in EU4 and the UK
8.5.2. Vaccine Eligible Pool of Chlamydia in EU4 and the UK
8.5.3. Gender-specific Incident Cases of Chlamydia in EU4 and the UK
8.5.4. Symptom-specific Incident Cases of Chlamydia in EU4 and the UK
8.5.5. Age-specific Incident Cases of Chlamydia in EU4 and the UK
8.5.6. Treated Cases of Chlamydia in EU4 and the UK
8.6. Japan
8.6.1. Total Fina Elf Incident Cases of Chlamydia in Japan
8.6.2. Vaccine Eligible Pool of Chlamydia in Japan
8.6.3. Gender-specific Incident Cases of Chlamydia in Japan
8.6.4. Symptom-specific Incident Cases of Chlamydia in Japan
8.6.5. Age-specific Incident Cases of Chlamydia in Japan
8.6.6. Treated Cases of Chlamydia in Japan

9. Patient Journey of Chlamydia
9.1. Patient Description

10. Emerging Therapies
10.1. Emerging Competitive Landscape of Chlamydia
10.2. SP0269 (mRNA vaccine): Sanofi
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.3.1. Clinical Trial Information
10.2.4. Safety and Efficacy
10.2.5. Analyst Views
List to be continued..

11. Chlamydia: Seven Major Market Analysis
11.1. Key Findings
11.2. Market Outlook of Chlamydia
11.3. Conjoint Analysis of Chlamydia
11.4. Key Market Forecast Assumptions
11.4.1. Cost Assumptions
11.4.2. Pricing Trends
11.4.3. Analogue Assessment
11.4.4. Launch Year and Therapy Uptakes
11.5. Total Fina Elf Market Size of Chlamydia in the 7MM
11.6. The United States
11.6.1. Total Fina Elf Market Size of Chlamydia in the United States
11.6.2. Market Size of Chlamydia by Therapies in the United States
11.7. EU4 and the UK
11.7.1. Total Fina Elf Market Size of Chlamydia in EU4 and the UK
11.7.2. Market Size of Chlamydia by Therapies in EU4 and the UK
11.8. Japan
11.8.1. Total Fina Elf Market Size of Chlamydia in Japan
11.8.2. Market Size of Chlamydia by Therapies in Japan

12. Unmet Needs of Chlamydia

13. SWOT Analysis of Chlamydia

14. KOL Views of Chlamydia
15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Chlamydia
16.1. The US
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17. Appendix
17.1. Bibliography
17.2. Report Methodology

For more information about this report visit https://www.researchandmarkets.com/r/yzrfvb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900